IN2014DN11099A - - Google Patents
Info
- Publication number
- IN2014DN11099A IN2014DN11099A IN11099DEN2014A IN2014DN11099A IN 2014DN11099 A IN2014DN11099 A IN 2014DN11099A IN 11099DEN2014 A IN11099DEN2014 A IN 11099DEN2014A IN 2014DN11099 A IN2014DN11099 A IN 2014DN11099A
- Authority
- IN
- India
- Prior art keywords
- liposomal irinotecan
- leucovorin
- fluorouracil
- administered
- patient
- Prior art date
Links
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 2
- 229960004768 irinotecan Drugs 0.000 abstract 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- 235000008191 folinic acid Nutrition 0.000 abstract 1
- 239000011672 folinic acid Substances 0.000 abstract 1
- 229960001691 leucovorin Drugs 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261659211P | 2012-06-13 | 2012-06-13 | |
US201361784382P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/045495 WO2013188586A1 (en) | 2012-06-13 | 2013-06-12 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN11099A true IN2014DN11099A (es) | 2015-09-25 |
Family
ID=48692681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN11099DEN2014 IN2014DN11099A (es) | 2012-06-13 | 2013-06-12 |
Country Status (22)
Country | Link |
---|---|
US (10) | US9452162B2 (es) |
EP (3) | EP3919048A1 (es) |
JP (3) | JP6310911B2 (es) |
KR (3) | KR101997206B1 (es) |
CN (2) | CN104717961A (es) |
AU (3) | AU2013202947B2 (es) |
BR (1) | BR112014031088A8 (es) |
CA (1) | CA2875824C (es) |
DK (2) | DK2861210T3 (es) |
ES (2) | ES2632915T3 (es) |
HK (2) | HK1209627A1 (es) |
IL (3) | IL235937B (es) |
IN (1) | IN2014DN11099A (es) |
MX (1) | MX2014015391A (es) |
NZ (1) | NZ702469A (es) |
PL (2) | PL3266456T3 (es) |
PT (2) | PT2861210T (es) |
RU (1) | RU2663450C2 (es) |
SI (2) | SI3266456T1 (es) |
TW (3) | TWI630924B (es) |
WO (1) | WO2013188586A1 (es) |
ZA (1) | ZA201408804B (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4971142B2 (ja) | 2004-05-03 | 2012-07-11 | ヘルメス バイオサイエンシズ インコーポレーティッド | 薬物送達に有用なリポソーム |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
JP6758195B2 (ja) * | 2014-01-14 | 2020-09-23 | ネクター セラピューティクス | 併用ベースの治療方法 |
MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
EP3229802A1 (en) * | 2014-12-09 | 2017-10-18 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
TW201701880A (zh) * | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びparp阻害薬を使用する併用療法 |
WO2017034957A1 (en) * | 2015-08-21 | 2017-03-02 | Merrimack Pharmaceuticals, Inc. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
DK3349731T3 (da) | 2015-09-16 | 2024-01-08 | Univ Texas | Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft |
JP6941606B2 (ja) | 2015-10-16 | 2021-09-29 | イプセン バイオファーム リミティド | 安定化カンプトテシン医薬組成物 |
WO2017172678A1 (en) * | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
JP2019516693A (ja) * | 2016-05-18 | 2019-06-20 | イプセン バイオファーム リミティド | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
CN110402163A (zh) * | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
CN113164600A (zh) * | 2018-10-17 | 2021-07-23 | 百欧林纳克斯有限公司 | 转移性胰脏腺癌的治疗 |
WO2020148745A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
WO2021142202A1 (en) | 2020-01-10 | 2021-07-15 | R-Pharm Us Operating Llc | Compositions of ixabepilone |
EP4087535A1 (en) | 2020-01-10 | 2022-11-16 | Tyndall Formulation Services, LLC | Formulations of sn-38 with poly(amino acid) block polymers |
US11286344B2 (en) | 2020-01-10 | 2022-03-29 | Tyndall Formulation Services, LLC | Polymer excipients for drug delivery applications |
WO2023056485A1 (en) * | 2021-10-03 | 2023-04-06 | Systimmune, Inc. | Methods of treating cancer and the pharmaceutical compositions thereof |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2628659A (en) * | 1951-01-17 | 1953-02-17 | Charles R Carpenter | Convertible furniture article |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
US6110491A (en) | 1996-10-22 | 2000-08-29 | Hermes Biosciences, Inc. | Compound-loaded liposomes and methods for their preparation |
US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
BR9914601A (pt) | 1998-09-16 | 2001-10-23 | Alza Corp | Inibidor de topoisomerase capturado por lipossoma |
US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
DE60123583T2 (de) | 2000-02-04 | 2007-08-09 | Lipoxen Technologies Ltd. | Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome |
US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
DK1286671T3 (da) | 2000-05-15 | 2006-07-17 | Celgene Corp | Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan |
EP1299084B1 (en) | 2000-06-30 | 2005-11-16 | Inex Pharmaceuticals Corp. | Liposomal antineoplastic drugs and uses thereof |
TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
US7108863B2 (en) | 2001-03-26 | 2006-09-19 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
EP1408972A2 (en) | 2001-07-23 | 2004-04-21 | Epidauros Biotechnologie AG | Methods for treatment of cancer with irinotecan based on mdr1 |
US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
ITBO20010610A1 (it) | 2001-10-05 | 2003-04-05 | Haworth S P A | Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo |
EP3100719A3 (en) | 2002-05-15 | 2017-02-22 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
EP1539207A4 (en) | 2002-05-31 | 2008-01-02 | Transmolecular Inc | TREATMENT OF CELL PROLIFERATION DISORDERS USING CHLOROTOXIN |
AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
EP1629010A1 (en) | 2003-05-30 | 2006-03-01 | Genentech, Inc. | Treatment with anti-vegf antibodies |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
JP4971142B2 (ja) | 2004-05-03 | 2012-07-11 | ヘルメス バイオサイエンシズ インコーポレーティッド | 薬物送達に有用なリポソーム |
EA011612B1 (ru) | 2004-06-01 | 2009-04-28 | Терумо Кабусики Кайся | Состав с иринотеканом |
AU2005249201A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with irinotecan (CPT-11) and an EGFR-inhibitor |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
WO2007050784A2 (en) | 2005-10-25 | 2007-05-03 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
EP1976485A4 (en) * | 2005-12-22 | 2011-10-26 | Celator Pharmaceuticals Inc | LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR THE PREPARATION OF SAID FORMULATIONS |
EP2338487B1 (en) | 2006-01-17 | 2013-09-11 | Abbott Laboratories | Combination therapy with PARP inhibitors |
CN101442998B (zh) | 2006-03-16 | 2012-03-14 | 比奥纽默里克药物公司 | 抗癌活性加强化合物和制剂及其用法 |
EP3248617A3 (en) | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
WO2009097011A1 (en) | 2007-08-17 | 2009-08-06 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
AU2008303466A1 (en) * | 2007-09-28 | 2009-04-02 | Universitatsspital Basel | Immunoliposomes for treatment of cancer |
CN101918003A (zh) | 2007-11-12 | 2010-12-15 | 彼帕科学公司 | 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌 |
CN101888777A (zh) | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症 |
TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
EP2259797A2 (en) | 2008-03-25 | 2010-12-15 | Schering Corporation | Methods for treating or preventing colorectal cancer |
US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
ES2525065T3 (es) | 2008-04-11 | 2014-12-17 | Merrimack Pharmaceuticals, Inc. | Ligadores de seroalbúmina humana y sus conjugados |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
AU2008362109B2 (en) * | 2008-09-26 | 2015-08-27 | Institut De Cancerologie De L'ouest | Individual 5-fluorouracile dose optimization in FOLFIRI treatment |
KR20110112301A (ko) | 2008-11-18 | 2011-10-12 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
JP2012525371A (ja) | 2009-05-01 | 2012-10-22 | オンコザイム・ファーマ・インコーポレイテッド | 癌を治療するためのペンタミジンの組み合わせ |
HUE027467T2 (en) | 2009-12-03 | 2016-10-28 | Jiangsu Hengrui Medicine Co | Liposomes or hydrochlorides of irinotecan and their preparation method |
MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
US20130274281A1 (en) | 2010-07-19 | 2013-10-17 | Bipar Sciences, Inc. | Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan |
CN103168104B (zh) | 2010-07-22 | 2016-09-28 | 加利福尼亚大学董事会 | 抗肿瘤抗原抗体及其使用方法 |
WO2012031293A1 (en) | 2010-09-03 | 2012-03-08 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of cancer |
CA2820245A1 (en) | 2010-12-06 | 2012-06-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents |
US9226984B2 (en) | 2010-12-14 | 2016-01-05 | Technical University of Denmark and Rigshospitalet | Entrapment of radionuclides in nanoparticle compositions |
CA2827118A1 (en) | 2011-02-15 | 2012-08-23 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
BR112013027021A2 (pt) | 2011-04-19 | 2016-11-29 | Merrimack Pharmaceuticals Inc | anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos |
JO3283B1 (ar) * | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
WO2013138371A1 (en) * | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
CA2881928A1 (en) | 2012-04-17 | 2013-10-24 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
AU2013374248A1 (en) | 2012-12-14 | 2015-06-11 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
EP2979700B1 (en) | 2013-03-27 | 2018-09-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent including low dose irinotecan hydrochloride hydrate |
US10111871B2 (en) | 2013-08-27 | 2018-10-30 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
US20160303264A1 (en) | 2013-10-23 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for non-invasive imaging and drug delivery |
EP3229802A1 (en) | 2014-12-09 | 2017-10-18 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
TW201701880A (zh) | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びparp阻害薬を使用する併用療法 |
WO2017034957A1 (en) | 2015-08-21 | 2017-03-02 | Merrimack Pharmaceuticals, Inc. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
JP6941606B2 (ja) | 2015-10-16 | 2021-09-29 | イプセン バイオファーム リミティド | 安定化カンプトテシン医薬組成物 |
US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
JP2019516693A (ja) | 2016-05-18 | 2019-06-20 | イプセン バイオファーム リミティド | 小細胞肺がんの治療に使用するためのナノリポソームイリノテカン |
CN110402163A (zh) | 2016-11-02 | 2019-11-01 | 易普森生物制药有限公司 | 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌 |
-
2013
- 2013-04-08 AU AU2013202947A patent/AU2013202947B2/en active Active
- 2013-06-11 TW TW102120630A patent/TWI630924B/zh active
- 2013-06-11 TW TW107116721A patent/TW201831168A/zh unknown
- 2013-06-11 TW TW108132921A patent/TWI729492B/zh active
- 2013-06-12 ES ES13731230.2T patent/ES2632915T3/es active Active
- 2013-06-12 EP EP21171689.9A patent/EP3919048A1/en active Pending
- 2013-06-12 PT PT137312302T patent/PT2861210T/pt unknown
- 2013-06-12 PT PT171690985T patent/PT3266456T/pt unknown
- 2013-06-12 EP EP17169098.5A patent/EP3266456B1/en active Active
- 2013-06-12 ES ES17169098T patent/ES2880089T3/es active Active
- 2013-06-12 KR KR1020177024678A patent/KR101997206B1/ko active IP Right Grant
- 2013-06-12 DK DK13731230.2T patent/DK2861210T3/en active
- 2013-06-12 KR KR1020197018996A patent/KR20190107010A/ko not_active Application Discontinuation
- 2013-06-12 PL PL17169098T patent/PL3266456T3/pl unknown
- 2013-06-12 BR BR112014031088A patent/BR112014031088A8/pt not_active Application Discontinuation
- 2013-06-12 MX MX2014015391A patent/MX2014015391A/es active IP Right Grant
- 2013-06-12 CA CA2875824A patent/CA2875824C/en active Active
- 2013-06-12 AU AU2013274287A patent/AU2013274287B2/en active Active
- 2013-06-12 CN CN201380036765.4A patent/CN104717961A/zh active Pending
- 2013-06-12 IL IL235937A patent/IL235937B/en unknown
- 2013-06-12 RU RU2015100529A patent/RU2663450C2/ru active
- 2013-06-12 IL IL294886A patent/IL294886A/en unknown
- 2013-06-12 US US14/406,776 patent/US9452162B2/en active Active
- 2013-06-12 IN IN11099DEN2014 patent/IN2014DN11099A/en unknown
- 2013-06-12 CN CN201910188153.6A patent/CN110051631A/zh active Pending
- 2013-06-12 WO PCT/US2013/045495 patent/WO2013188586A1/en active Application Filing
- 2013-06-12 NZ NZ702469A patent/NZ702469A/en unknown
- 2013-06-12 PL PL13731230T patent/PL2861210T3/pl unknown
- 2013-06-12 JP JP2015517405A patent/JP6310911B2/ja active Active
- 2013-06-12 KR KR1020157000450A patent/KR101776808B1/ko active IP Right Grant
- 2013-06-12 SI SI201331912T patent/SI3266456T1/sl unknown
- 2013-06-12 DK DK17169098.5T patent/DK3266456T3/da active
- 2013-06-12 SI SI201330697T patent/SI2861210T1/sl unknown
- 2013-06-12 EP EP13731230.2A patent/EP2861210B1/en not_active Revoked
-
2014
- 2014-12-02 ZA ZA2014/08804A patent/ZA201408804B/en unknown
-
2015
- 2015-07-29 US US14/812,950 patent/US9339497B2/en active Active
- 2015-09-03 US US14/844,500 patent/US9364473B2/en active Active
- 2015-09-11 US US14/851,111 patent/US9492442B2/en active Active
- 2015-10-22 HK HK15110395.3A patent/HK1209627A1/xx not_active IP Right Cessation
-
2016
- 2016-03-03 US US15/059,640 patent/US20160228428A1/en not_active Abandoned
- 2016-11-02 US US15/341,377 patent/US20170065578A1/en not_active Abandoned
-
2017
- 2017-06-08 JP JP2017113465A patent/JP2017149783A/ja not_active Withdrawn
- 2017-07-18 US US15/652,513 patent/US20170368056A1/en not_active Abandoned
-
2018
- 2018-03-19 AU AU2018201942A patent/AU2018201942B2/en active Active
- 2018-06-19 US US16/012,351 patent/US10980795B2/en active Active
- 2018-07-04 HK HK18108641.6A patent/HK1248608A1/zh unknown
-
2019
- 2019-05-07 JP JP2019087488A patent/JP6857210B2/ja active Active
-
2021
- 2021-03-17 US US17/204,278 patent/US20220096458A1/en active Pending
-
2023
- 2023-07-20 IL IL304631A patent/IL304631A/en unknown
-
2024
- 2024-03-22 US US18/613,609 patent/US20240226090A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN11099A (es) | ||
PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
MY189466A (en) | Methods of modulating drug plasma levels using erythrohydroxybupropion | |
NZ631144A (en) | Compositions and methods for transmucosal absorption | |
NZ711373A (en) | Fragments of p97 and uses thereof | |
TN2013000508A1 (en) | Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer | |
MX2020012924A (es) | Terapias combinadas de coenzima q10 para el tratamiento de cancer. | |
IN2014DN09098A (es) | ||
IN2015DN03219A (es) | ||
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
SG195110A1 (en) | Pirfenidone and anti-fibrotic therapy in selected patients | |
GB201111485D0 (en) | Drug composition and its use in therapy | |
PH12014502738A1 (en) | High-xten fusion protein and its use in the treatment of growth hormone deficiency | |
MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
MX2015012899A (es) | Pirrolo [2,3-b] piridina como inhibidores de quinasa cdk9. | |
WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT | |
NZ594414A (en) | Fused amino pyridines for the treatment of brain tumors | |
EP2836217A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
MX2014013491A (es) | Metodos para mantener, tratar o mejorar la funcion cognitiva. | |
UA88769U (uk) | Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності | |
UA74769U (ru) | Способ лечения больных со стеатозом печени, совмещенным с хроническим безкаменным холециститом | |
UA75714U (uk) | Спосіб лікування хронічного вірусного гепатиту с, асоційованого з фіброзом печінки |